Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Canadians warn patients against Avandia
More limits on Avandia use, this time from Canadian regulators. While the FDA continues to debate adding various warnings to GlaxoSmithKline's embattled diabetes drug, HealthCanada has induced GSK to release new, restrictive guidelines.
According to GSK's Dear Doctor letter, the drug should never be used in a patient with heart failure, not even in the early stages. The drug can be added to metformin treatment, but only if metformin alone doesn't work. And Avandia should only be used on its own or with sulfa drugs if the patient can't tolerate metformin or has tried metformin without success. And it shouldn't be taken with insulin.
- see the "Dear Health Care Professional" letter at HealthCanada
- check out this item at Pharmalot
- read the report from The Record
Related Articles:
Avandia cleared FDA by one vote. Report
GSK plant closure begins 5,000 job cuts. Report
Teva inks deal to sell generic Avandia. Report
Avandia, Actos don't boost death risk. Report
FDA adds to drumbeat of bad news for Avandia. Report
Expert committee says Avandia should stay. Report
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


